BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.100-3.250 for the period, compared to the consensus earnings per share estimate of 2.040. The company issued revenue guidance of $2.8 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.
BioMarin Pharmaceutical Stock Performance
Shares of BioMarin Pharmaceutical stock opened at $69.13 on Tuesday. The business’s 50 day moving average price is $85.26 and its 200 day moving average price is $84.14. The company has a market cap of $13.13 billion, a price-to-earnings ratio of 64.61, a PEG ratio of 1.03 and a beta of 0.32. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05. BioMarin Pharmaceutical has a one year low of $68.83 and a one year high of $99.56.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.39. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. The firm had revenue of $712.03 million for the quarter, compared to analysts’ expectations of $660.51 million. On average, research analysts predict that BioMarin Pharmaceutical will post 2.4 EPS for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on BioMarin Pharmaceutical
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Recommended Stories
- Five stocks we like better than BioMarin Pharmaceutical
- What is the Euro STOXX 50 Index?
- 4 Reasons GlobalFoundries Could Be a Big Winner After Recent Lows
- The How And Why of Investing in Oil Stocks
- The Average 401k Balance by Age Explained
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.